Ariad Pharmaceuticals Inc
ARIA
ARIA was delisted on the 15th of February, 2017.
203 hedge funds and large institutions have $2.29B invested in Ariad Pharmaceuticals Inc in 2016 Q3 according to their latest regulatory filings, with 49 funds opening new positions, 63 increasing their positions, 62 reducing their positions, and 28 closing their positions.
120% more capital invested
Capital invested by funds: $1.04B → $2.29B (+$1.25B)
75% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 28
14% more funds holding in top 10
Funds holding in top 10: 7 → 8 (+1)
12% more funds holding
Funds holding: 182 → 203 (+21)
2% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 62
26% less call options, than puts
Call options by funds: $29.1M | Put options by funds: $39.1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$172M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$91.1M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$59.7M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$25.5M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
+$24.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$82.3M |
| 2 |
Westfield Capital Management
Boston,
Massachusetts
|
-$45.9M |
| 3 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$29.6M |
| 4 |
ECP
Elk Creek Partners
Denver,
Colorado
|
-$11.7M |
| 5 |
JIM
Jupiter Investment Management
London,
United Kingdom
|
-$9.94M |
ARIA Hedge Fund Activity: Q3 2016 in Review
203 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Ariad Pharmaceuticals Inc (ARIA) for Q3 2016, worth a combined $2.29B — up 120% from $1.04B a quarter earlier.
Buyers outnumbered sellers: 49 funds opened new ARIA positions and 28 closed out — a net gain of 21 holders — while 63 added to existing stakes and 62 trimmed.
The largest buyer was Wellington Management Group, opening a new position worth an estimated $172M. The largest seller was Putnam Investments, cutting an estimated $82.3M.
- 203 institutional investors held Ariad Pharmaceuticals Inc (ARIA) as of Q3 2016, up from 182 in Q2 2016.
- Funds reported $2.29B of Ariad Pharmaceuticals Inc stock for Q3 2016, up 120% quarter-over-quarter.
- 49 funds opened new Ariad Pharmaceuticals Inc positions in Q3 2016 and 28 closed out, a net change of +21 holders.
- The largest Ariad Pharmaceuticals Inc buyer in Q3 2016 was Wellington Management Group, an estimated $172M added.
- The largest Ariad Pharmaceuticals Inc seller in Q3 2016 was Putnam Investments, an estimated $82.3M sold.
Based on aggregated 13F filings for Q3 2016.